NCT07610928

Brief Summary

Many Asian Americans with depression also struggle with physical symptoms-such as pain, fatigue, or other forms of bodily discomfort-that occur at the same time. Right now, there is no proven treatment that effectively addresses both the depression and these physical symptoms together. This study will test whether it is practical, acceptable, and safe to combine the Stress Management and Resiliency Training (SMART) program with meditative movements for people who have both major depression and these distressing physical symptoms.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
15mo left

Started Jun 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Jun 2026Aug 2027

First Submitted

Initial submission to the registry

May 7, 2026

Completed
21 days until next milestone

First Posted

Study publicly available on registry

May 28, 2026

Completed
4 days until next milestone

Study Start

First participant enrolled

June 1, 2026

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2027

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2027

Last Updated

May 28, 2026

Status Verified

May 1, 2026

Enrollment Period

10 months

First QC Date

May 7, 2026

Last Update Submit

May 20, 2026

Conditions

Keywords

DepressionAsian AmericanSomatic symptoms

Outcome Measures

Primary Outcomes (2)

  • Feasibility of Recruitment, Eligibility Criteria, SMART-QTC and Control Interventions, and Videoconferencing Procedures

    Recruitment feasibility targets are: \>=70% consent to screening, \>=70% meeting screening criteria, \>=70% of eligible individuals enrolling, and enrollment of \>=20 participants/month. Eligibility feasibility will include the proportion ineligible due to each criterion (\<20%), reasons for ineligibility, reasons for refusal, and characteristics of refusers. SMART-QTC and control intervention feasibility will include adherence (\>=75% session attendance), retention (\>=75% completion of post-assessments and \>=70% completion of follow-up assessments), fidelity (checklist score \>=80%), and home practice completion (\>=75% completing home practice at least 3 days/week). Videoconferencing feasibility will include \<20% dropped connections, \<20% missed sessions due to technical problems, mean number of technical problems \<2.0, types of technical problems, and \<20% requesting extra training, type of extra training needed.

    From screening to the end of assessments at week 12

  • Acceptability of SMART-QTC and Control Interventions and Videoconferencing Procedures

    Acceptability of SMART-QTC and control interventions will be assessed using post-session surveys, post-intervention surveys, exit interviews, and follow-up surveys. Outcomes include session satisfaction, helpfulness, enjoyment, relevance, and utility of each session component rated on a 5-point scale (1=not at all to 5=very much; mean \>=3.75). Overall program satisfaction, likelihood of continued skill use, and willingness to recommend the program to others will also target mean ratings \>=3.75 on a 5-point scale. Exit interviews will assess likes, dislikes, and suggestions for improvement. \>=60% of participants continuing meditation practice at follow-up. Videoconferencing acceptability will include ease and confidence of use (1=not at all, 5=extremely, mean \>=3.75), interference of technical problems (1=none, 5=extreme, mean \<1.0), audiovisual quality and overall satisfaction (1=poor, 5=excellent, mean\>=3.75), and pros and cons and suggestions for improvement.

    From enrollment to the end of assessments at week 12

Secondary Outcomes (2)

  • Patient Health Questionnaire-15 (PHQ-15)

    From screening to the end of assessments at week 12

  • Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Distress-Depression-Short Form

    From screening to the end of assessments at week 12

Study Arms (2)

Healthy Living Program

ACTIVE COMPARATOR
Behavioral: Healthy Living Program

SMART-QTC

EXPERIMENTAL
Behavioral: Stress Management and Resiliency Training with Qigong/Tai Chi

Interventions

The SMART-QTC will be an 8-session online intervention with 1.5-hour weekly sessions that include core elements of SMART, including mind-body practice based on RR training, cognitive behavioral skills, and positive psychological skills, with QTC exercises incorporated at the end of every session.

SMART-QTC

The Healthy Living Program is an 8-session program designed to incorporate psychoeducation on a range of key health behaviors and wellness topics, including: the comorbidity between mental and physical illness, sleep, physical exercise, nutrition, and managing health-care needs. The course encourages in-group and at-home self-monitoring and practice of healthy living principles.

Healthy Living Program

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Self-identify as being of Asian ethnicity
  • English language proficiency
  • Be ≥18 years of age
  • Satisfy DSM-5 criteria for MDD prior to the initiation of the study intervention, as determined by the Mini International Neuropsychiatric Interview (MINI) interview
  • A baseline of the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression score ≥ 16
  • A baseline score of PHQ-15 ≥10
  • Have not had Tai Chi/Qigong training/practice or other forms of mind-body intervention (e.g. yoga, mindfulness training, muscle relaxation training, etc) more than once a week in the past 3 months
  • A total score 24 or higher in Mini-Mental Status Examination for cognitive ability (if the participant endorses a history of cognitive impairment).
  • Willing to keep any psychiatric medications and psychotherapy stable throughout the course of the study (from Week 0 baseline to Week 12 Follow-up)
  • Have access to a device (i.e., smartphone, iPad, personal computer) and a stable network to attend the online group sessions
  • Ability to perform daily physical activity

You may not qualify if:

  • Have a primary psychiatric diagnosis other than MDD
  • Any history of psychosis, mania, or impulsivity and difficulty relating to people and judged by the clinician not appropriate for group intervention
  • Active eating disorder or substance use disorder within the last 6 months
  • Any relevant medical conditions that may be the medical basis of depression including thyroid diseases, epilepsy, history of an abnormal EEG, severe head trauma, or stroke
  • Have serious uncontrolled medical conditions (e.g. poorly controlled diabetes, severe congestive heart failure), or other medical conditions that in the opinion of the investigators represents a risk to the subject, including presence of a pacemaker, cardiac arrhythmia, fever, weakness and hypotension, or vagal nerve stimulator
  • current active suicidal or self-injurious potential (i.e., PHQ-9 item 9 ≥1 and/or a positive response to C-SSRS screener items 3, 4, 5, or 6), and assessed by the clinician necessitating immediate treatment
  • Participant who are or who plan to receive confounding treatments (including treatment of endocrinopathies): use of antidepressants, complementary and alternative medical (CAM) treatments thought to have beneficial effects on mood, including St. John's Wort, S-Adenosyl methionine (SAMe), omega-3 fatty acids, light therapy, conventional psychotherapy, mind-body interventions (e.g. Qigong, mindfulness training, muscle relaxation training, etc.)
  • Electroconvulsive therapy (ECT) during the last year as these patients are often among the more refractory and are not optimal candidates for CAM
  • History of refractory to treatment with ≥3 failed antidepressant trials in current depressive episode
  • Participated in other depression-related clinical trials within the past 3 months
  • Antidepressant or psychiatric medications that are initiated less than 8 weeks or a dose change less than 4 weeks prior to screening visit
  • Psychotherapy that has been initiated within the past 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

DepressionDepressive Disorder, MajorPsychological Well-BeingMedically Unexplained Symptoms

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorDepressive DisorderMood DisordersMental DisordersPersonal SatisfactionSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinician Investigator, Full Professor

Study Record Dates

First Submitted

May 7, 2026

First Posted

May 28, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

August 31, 2027

Last Updated

May 28, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share